Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

Professor of Medical Oncology
Director, Yonsei Song-Dang Institute for Cancer Research
Yonsei University College of Medicine
Seoul, Korea

Related Videos

What have we learned from the recent trials looking at the ability of NGS to drive precision-based treatments across a broad spectrum of tumor subtypes? (Korean) Video

What have we learned from the recent trials looking at the ability of NGS to drive precision-based treatments across a broad spectrum of tumor subtypes? (Korean)

What have we learned from the recent trials looking at the ability of NGS to drive precision-based treatments across a broad spectrum of tumor subtypes?

What specific information, variances, actionable guidance, and clinical/biological interpretations are provided on a NGS pathology report? How do you apply an NGS report clinically? (Korean) Video

What specific information, variances, actionable guidance, and clinical/biological interpretations are provided on a NGS pathology report? How do you apply an NGS report clinically? (Korean)

What specific information, variances, actionable guidance, and clinical/biological interpretations are provided on a NGS pathology report? How do you apply an NGS report clinically?

What is the evidence that personalized, gene-directed therapy, in which molecular drivers identified by NGS produce treatments that are better aligned with actionable targets, will improve outcomes? Video

What is the evidence that personalized, gene-directed therapy, in which molecular drivers identified by NGS produce treatments that are better aligned with actionable targets, will improve outcomes?

What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers identified by NGS will produce treatments that are better aligned with actionable targets and will improve patient outcomes?

How do you prioritize the genomic information provided by NGS and how do you curate the importance of alterations, rearrangements, and fusion events reported by NGS? (Korean) Video

How do you prioritize the genomic information provided by NGS and how do you curate the importance of alterations, rearrangements, and fusion events reported by NGS? (Korean)

How do you prioritize the genomic information provided by NGS and how do you curate the importance of alterations, rearrangements, and fusion events reported by NGS?

In South Korea, how is NGS playing an increasingly important role in the Yonsei Cancer Center in the genomic profiling of cancer and to guide selection of oncology treatment? (Korean) Video

In South Korea, how is NGS playing an increasingly important role in the Yonsei Cancer Center in the genomic profiling of cancer and to guide selection of oncology treatment? (Korean)

In South Korea, how is NGS playing an increasingly important role in the Yonsei Cancer Center in the genomic profiling of cancer and to guide selection of oncology treatment?

For what solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying disease alleles which can reliably guide the use of molecularly targeted therapy? Video

For what solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying disease alleles which can reliably guide the use of molecularly targeted therapy?

For what specific solid tumors and hematologic malignancies has NGS genomic profiling shown to be most valuable for identifying disease alleles which can reliably guide the use of molecularly targeted therapy?

What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes? Video

What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes?

What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with ...

What guidance can you give when the F1M CGP profile reveals multiple actionable mutations? Why select targeted therapies when multiple genomic alterations or rearrangements co-exist? Video

What guidance can you give when the F1M CGP profile reveals multiple actionable mutations? Why select targeted therapies when multiple genomic alterations or rearrangements co-exist?

What guidance can you give in those cases in which the F1M CGP profile reveals multiple actionable mutations? On what basis would you select targeted therapies when multiple significant genomic alterations or rearrangements co-exist?

What common mutations and rearrangements--among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS-- present in tumors represent the best molecular targets for cancer therapy? Video

What common mutations and rearrangements--among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS-- present in tumors represent the best molecular targets for cancer therapy?

What common mutations and rearrangements—among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS— present in tumors represent the best molecular targets for cancer therapy? Are some more predictive of success with targeted therapy than others? Why?